{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-099376","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.441321+00:00","generated_at":"2026-05-15T16:56:59.618596+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SAB-142 Phase 1 data shows C-peptide preservation in established T1D patients at Day 120","bullets":["T1D cohort (n=6): 4 treated with SAB-142 (2.5 mg/kg) showed no decline in C-peptide at Day 120; mean values increased above baseline.","Placebo participant (n=1) showed C-peptide decline consistent with predicted disease progression.","Biomarker evidence of T cell exhaustion supports mechanism of action, per KOL Michael Haller, MD.","SAFEGUARD Phase 2b trial enrolling new-onset Stage 3 T1D patients; topline data expected 2H 2027.","Phase 1 previously met safety/PD objectives, enabling advancement to registrational trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-099376","json":"https://secwatch.observer/filing/0001193125-26-099376.json","markdown":"https://secwatch.observer/filing/0001193125-26-099376.md","text":"https://secwatch.observer/filing/0001193125-26-099376.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526099376/0001193125-26-099376-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526099376/sabs-20260310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T16:56:59.618596+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}